KRAS G12S is a hotspot oncogenic gain-of-function mutation (Figure 2B), whereas the biological effect of SMAD4 P356L is unclear (Table 2), although this mutation is recurrent in various cancers (Figure 2C) and is predicted to be oncogenic [9,10]. This evidence concerns the gene KRAS and cancer.